PE-22-28 10mg Dosage Protocol

Educational guide for reconstitution and administration of PE-22-28, an epidermal growth factor peptide studied for skin regeneration.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (2 mL = 5 mg/mL)

Frequency: Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. Note: A single 10 mg vial provides only 2–4 days of research material at these doses.

Reconstitution Steps

1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Biological Action

PE-22-28 represents a synthetic peptide fragment corresponding to residues 22-28 of human epidermal growth factor (EGF), designed to retain EGF-like activity with enhanced stability.

As an EGF receptor agonist, PE-22-28 binds to epidermal growth factor receptors to stimulate cellular proliferation, migration, and differentiation in skin and epithelial tissues.

PE-22-28 has been studied extensively for its role in wound healing and skin regeneration in research contexts.

Potential Benefits & Side Effects

Findings from wound healing and dermatological research.

• Potential to support wound healing and skin regeneration in research settings
• May assist with epithelial tissue repair and cellular proliferation studies
• Associated with EGF receptor activation and skin barrier function
• Generally well tolerated; occasional mild skin irritation or local reactions
• Human safety profile remains under investigation; not approved for therapeutic use
• Long-term human safety data not established; this compound remains investigational

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Slow injection may minimize any stinging sensation associated with the compound.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
• Document daily dose and site rotation to maintain consistency.
• The 10 mg vial format is suited for short-term tolerance assessment; extended protocols require multiple vials.

References